Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026

Rhea-AI Summary

Tenaya Therapeutics (NASDAQ: TNYA) will present at the Leerink Partners Global Healthcare Conference in Miami from March 9-11, 2026. CEO Faraz Ali will join a fireside chat on March 9, 2026 at 1:00 pm ET. A live webcast will stream via the company Investors site, with an archived replay available for approximately 30 days.

News Market Reaction – TNYA

-3.51%

-3.51% Session close to close

In the Mar 3 session, TNYA declined 3.51%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Tenaya’s participation in a major healthcare conference, with a firesid...

Analysis

This announcement highlights Tenaya’s participation in a major healthcare conference, with a fireside chat on March 9, 2026 and a webcast replay available for 30 days. In recent months, the company has combined strategic updates, financings, and gene-therapy data releases, some of which coincided with sharp price moves. Investors may focus on upcoming clinical readouts, funding runway milestones, and any new disclosures that emerge around conference appearances.

Key Figures

Conference dates: March 9–11, 2026 Fireside chat date: March 9, 2026 Fireside chat time: 1:00 pm ET +1 more

4 metrics

Conference dates March 9–11, 2026 Leerink Partners Global Healthcare Conference

Fireside chat date March 9, 2026 CEO participation at conference

Fireside chat time 1:00 pm ET Scheduled presentation time

Webcast archive duration 30 days Replay availability after conference

Historical Context

5 past events · Latest: Jan 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 09	Strategic update	Positive	-1.0%	Outlined 2026 priorities, clinical milestones and funding runway through mid-2027.
Dec 12	Equity offering	Negative	-37.5%	Priced public offering of 50M units at $1.20 with attached warrants.
Dec 11	Offering proposal	Negative	-37.5%	Announced intent to offer stock and warrant units under existing Form S-3.
Dec 11	Clinical hold lifted	Positive	-37.5%	FDA removed clinical hold on MyPEAK-1 trial of TN-201 after protocol changes.
Dec 11	Clinical data update	Positive	-37.5%	Reported positive interim RIDGE-1 TN-401 data with PVC reductions and tolerability.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows predominantly negative price reactions, including sharp declines on both dilutive offerings and ostensibly positive clinical/regulatory updates.

Recent Company History

Over the last several months, Tenaya reported positive clinical and strategic updates alongside dilutive financing. In December 2025, a proposed and then priced public offering coincided with -37.5% moves, while the lifting of an FDA clinical hold for TN-201 and positive interim RIDGE-1 data also saw -37.5% reactions. A January 9, 2026 update outlining 2026 milestones and funding through mid-2027 saw a more modest -0.96% move. Today’s conference participation fits within this backdrop of volatile responses to news.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Company management will be participating in the upcoming Leerink Partners Global Healthcare Conference taking place from March 9-11, 2026 in Miami, Florida. Faraz Ali, Tenaya’s Chief Executive Officer, will participate in a fireside chat on Monday, March 9, 2026, at 1:00 pm ET.

The live webcast of the fireside chat may be accessed from the Investors section of Tenaya’s website. An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.

About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.

Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com

Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com

FAQ

When is Tenaya Therapeutics (TNYA) presenting at the Leerink Partners Global Healthcare Conference 2026?

Tenaya management will participate at the conference March 9-11, 2026. According to the company, CEO Faraz Ali will appear in a fireside chat on Monday, March 9, 2026 at 1:00 pm ET, as part of the firm’s scheduled conference participation.

How can investors watch the Tenaya Therapeutics (TNYA) fireside chat on March 9, 2026?

Investors can view a live webcast via Tenaya’s Investors website. According to the company, the webcast will stream live during the March 9, 2026 fireside chat and be accessible from the Investors section of Tenaya’s website.

Will Tenaya Therapeutics (TNYA) provide a replay of the conference webcast and for how long?

An archived replay will be available on Tenaya’s website for about 30 days following the conference. According to the company, the replay will remain accessible via the Investors section for approximately 30 days after the event ends.

Who from Tenaya Therapeutics (TNYA) is speaking at the Leerink Partners Global Healthcare Conference 2026?

Faraz Ali, Tenaya’s Chief Executive Officer, will participate in the fireside chat on March 9, 2026 at 1:00 pm ET. According to the company, management will be present across the March 9-11, 2026 conference sessions.

Where and when is the Leerink Partners Global Healthcare Conference 2026 taking place for Tenaya Therapeutics (TNYA)?

The conference runs March 9-11, 2026 in Miami, Florida. According to the company, Tenaya’s management will attend the Miami event, with the CEO’s fireside chat scheduled for March 9 at 1:00 pm ET.